Clinical Report: Epiretinal Membrane Removal May Reduce Injection Burden in nAMD
Overview
In a small retrospective study, the removal of epiretinal membranes (ERM) in patients with neovascular age-related macular degeneration (nAMD) was associated with a reduction in the burden of anti-VEGF injections. Two-thirds of patients either stopped or reduced their injection frequency following surgery.
Background
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss, and anti-VEGF injections are the standard treatment. However, some patients experience persistent cystoid macular edema despite therapy, necessitating alternative interventions. Understanding the impact of surgical options like ERM removal on treatment burden is crucial for optimizing patient care.
Data Highlights
| Parameter | Before Surgery | After Surgery | P-Value |
|---|---|---|---|
| Mean number of injections | 7.58 | 4.33 | 0.009 |
| Central retinal thickness (μm) | 328 | 288 | 0.092 |
Key Findings
- Two-thirds of patients stopped or reduced anti-VEGF injections after ERM removal.
- Mean number of injections decreased from 7.58 to 4.33 post-surgery (P=0.009).
- Four patients completely stopped injections, while four others had a reduced injection burden.
- Mean time to resumption of injections among those who resumed was 16.4 weeks.
- Central retinal thickness decreased from approximately 328 μm to 288 μm, though not statistically significant (P=0.092).
- Visual acuity did not change significantly post-surgery (P=0.081).
Clinical Implications
The findings suggest that surgical intervention for ERM in patients with treatment-resistant nAMD may lead to a reduced need for anti-VEGF injections. This could potentially alleviate the treatment burden for patients who are struggling with persistent edema despite ongoing therapy.
Conclusion
The study indicates that ERM removal may be a beneficial surgical option for patients with nAMD, leading to a significant reduction in anti-VEGF injection frequency. Further research is warranted to confirm these findings.
Related Resources & Content
- Jim Gallagher, Retinal Physician, 2026 -- Epiretinal Membrane Removal May Reduce Injection Burden in nAMD Recommendations
- Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA, Retinal Physician, 2024 -- Improving Durability of Drugs in Wet AMD
- Retinal Physician, 2020 -- Cryopreserved Amniotic Membrane for Intravitreal Injection
- Retinal Physician, 2022 -- Complications From Macular Peeling
- Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology, 2025
- TENAYA and LUCERNE - Ophthalmology, 2024
- Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration: A MOOSE-compliant meta-analysis - PMC
- Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
- TENAYA and LUCERNE - Ophthalmology
- Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration: A MOOSE-compliant meta-analysis - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







